Introduction {#s1}
============

In Spain, all resident women aged 50--69 are actively invited to participate in the population-based breast cancer screening program by written letter every 2 years. A screening mammogram (a type of low-dose x-ray examination used to detect breast cancer) is offered, allowing women who begin screening at 50--51 years up to a maximum of 10 screening mammograms. Breast cancer screening in Spain adheres to the European Guidelines for Quality Assurance in Mammographic Screening [@pone.0097459-Perry1] and its results meet the required standards [@pone.0097459-vonKarsa1], [@pone.0097459-Ascunce1].

Several studies have shown that digital mammography is more expensive than screen-film mammography [@pone.0097459-Ciatto1]--[@pone.0097459-MartnezCantarero1], requires a considerable initial financial outlay and that the cost reimbursement of the switch is marginal. Previous studies have also emphasized the benefits of the technical features of digital mammography: the image is visualized in a computer window instead of a hard copy, which precludes film processing, storage, copying and retrieval. These benefits revert at the logistic level within a screening program: mammograms are visualized, stored and retrieved more easily, and allow radiologists to manipulate the image (such as zooms or changes of brightness and contrast) without additional exposure of the woman to radiation and attendance to the hospital. Digital equipment was approved by the US Food and Drug Administration based on results showing similar efficacy to conventional mammography [@pone.0097459-White1]. The European guidelines for breast cancer screening recognize that digital mammography is likely to become established due to its advantages [@pone.0097459-Perry1]. However, the cost-effectiveness of this switch in population-based screening programs, which involve millions of women and millions of tests, is controversial and, to our knowledge, no budget impact analysis has been performed to date.

In Spain, screening units are increasingly switching to digital mammography as a consequence of digitalization of radiology departments. The US Preventive Services Task Force recommendations [@pone.0097459-US1], however, were based on the results of screening with screen-film mammography and consider that there is insufficient evidence to recommend digital mammography. The existing evidence on the effect of digital mammography in population-based breast cancer screening programs indicators is inconclusive: although the latest studies have found a slightly higher detection rate (number of cancers detected per 1,000 examinations) with digital mammography [@pone.0097459-Bluekens1], the main conclusion of review studies is that digital mammography is at least as good as screen-film [@pone.0097459-Skaane1]--[@pone.0097459-Iared1]. Recent studies in Spain [@pone.0097459-Sala1]--[@pone.0097459-Domingo1] have found a lower recall rate (percentage of women called back for further tests) for digital mammography and a similar cancer detection rate. In contrast, other studies have found significantly higher recall rates with digital mammography [@pone.0097459-Glynn1], [@pone.0097459-Nederend1]. Further recent findings indicate the number of invasive procedures is lower with digital mammography [@pone.0097459-Domingo1], [@pone.0097459-Timmers1] and that the tumoral characteristics detected [@pone.0097459-Domingo1], [@pone.0097459-Kerlikowske1] and interval cancer (primary breast cancer arising after a negative screening episode and before the next invitation to screening or within 24 months for women who reached the upper age limit) rates [@pone.0097459-Hoff1] are similar.

Budget impact analysis aims to estimate the impact of introducing a new technology in the budgets for the coming years [@pone.0097459-Mauskopf1]--[@pone.0097459-Mar1]. According to Mauskopf et al. [@pone.0097459-Mauskopf1], this type of analysis measures the impact of a new technology on the annual cost and annual health benefit, as well as other outcomes of interest, in the years after its introduction in a national health system or a private health plan. For the time being, Budget Impact Analysis has had a short run in the scientific literature since the format used generally consisted in simple models based on assumptions from the literature and often on expert opinion. In recent years several authors have proposed guidelines for its development with more stringent requirements and have provided the scientific status to Budget Impact Analysis [@pone.0097459-Mauskopf1]--[@pone.0097459-Mar1]. This type of analysis is especially important when assessing population-based programs in which small variations may affect a substantial proportion of the population.

In light of current findings, the economic impact of switching to digital mammography needs to be assessed. This impact includes not only the costs of mammography itself, but also the costs derived from performing a population-based screening program involving millions of women and tests, i.e., the costs of additional diagnostic tests and those of cancer treatment. The objective of the present study was to estimate the long-term impact on costs and health outcomes of switching from screen-film mammography to full-field digital mammography in a population-based breast cancer screening program from the perspective of a National Health System.

Methods and Materials {#s2}
=====================

Ethics Statement {#s2a}
----------------

This study was approved by the ethics committee of Hospital del Mar. The need for written informed consent was waived because all data was analyzed anonymously.

Discrete-event simulation model {#s2b}
-------------------------------

Discrete-event simulation has been defined as "a flexible modeling method characterized by the ability to represent complex behavior within, and interactions between individuals, populations, and their environments" [@pone.0097459-Karnon1]. A discrete-event simulation model was built to reproduce the process of women entering a population-based breast cancer screening program. The events simulated were as follows: inclusion of a new woman in the target population, participation in the screening program, a positive or negative result of screening (including screening mammography and additional tests), nonscreening cancer detection, exit from the target population, and death. The conceptual model was based on the European guidelines [@pone.0097459-Perry1] and is depicted in [Figure 1](#pone-0097459-g001){ref-type="fig"}.

![Flow chart of the conceptual model (screening \[a\] and natural history of cancer \[b\]).\
TN: true negative, FP: false positive, TP: true positive, FN: false negative.](pone.0097459.g001){#pone-0097459-g001}

Parallel to the events related to the screening program, each woman was assigned a natural history of breast cancer. These events consisted of the start of the pre-clinical stage (when the cancer appears but it is asymptomatic), the start of the clinical stage (when the cancer is symptomatic), and death ([Fig. 1](#pone-0097459-g001){ref-type="fig"}). The model allowed for the absence of progression but did not consider spontaneous cancer remission.

The time units were years. A simulated time horizon of 20 years (from 2010 to 2029) was chosen to encompass the life history of a woman entering a screening program (from 50 to 69 years) and to allow the budget impact to be analyzed in the long term. Individual women were simulated. Two identical groups of women with the same pattern of screening participation were simulated: one group by using the parameters estimated for screen-film mammography and the other by using parameters for full-field digital mammography. The times until an event of the natural history of breast cancer were also the same unless modified by cancer detection. All women underwent biennial screening from 50 to 69 years of age. Women aged 70 years or older were followed-up until 2029 only if they were diagnosed with cancer between the ages of 50 and 69 years or with an interval cancer in the last mammogram.

The simulation model was implemented by using Arena (Rockwell Software) version 13.9.

Target population {#s2c}
-----------------

The target population at the beginning of the simulation included 100,000 women aged 50-69 years undergoing biennial screening. Every 2 years, women aged 50--51 years old entered the target population, following the age structure of the Spanish population [@pone.0097459-INEbase1]. Women undergoing their last mammogram (aged 68--69) were excluded from the target population unless they were found to have breast cancer within the screening program or an interval cancer in the last mammogram (details of the estimation of the parameters and the simulation are provided in [Appendix S1](#pone.0097459.s001){ref-type="supplementary-material"}).

Natural history model parameters {#s2d}
--------------------------------

Breast cancer incidence [@pone.0097459-Rue1] was used to estimate the time until pre-clinical onset [@pone.0097459-Lee1], [@pone.0097459-Vilaprinyo1]. The duration of pre-clinical status was modeled according to age at pre-clinical onset [@pone.0097459-Lee2], ranging from 2 in 40-year-olds and increasing to 4 years after that age of 50 years (see the [appendix S1](#pone.0097459.s001){ref-type="supplementary-material"} for further details).

Age of death from any cause was modeled using the number of women and the number of deaths, by age, of the Spanish population in 2008 [@pone.0097459-INEbase1], [@pone.0097459-Roman1].

We assumed that if a woman enters the clinical stage, the cancer is detected on the basis of symptoms. Currently available data did not allow modeling the natural history of breast cancer based on progression through cancer stages, occurrence of symptoms or recurrences. Thus, the cancer stage was assigned according to the distributions described in the [appendix S1](#pone.0097459.s001){ref-type="supplementary-material"} for screening-detected and clinically-detected cancers. Survival according to stage and age at detection also depended on the birth cohort [@pone.0097459-Vilaprinyo2] (see the [appendix S1](#pone.0097459.s001){ref-type="supplementary-material"} for further details).

Screening events {#s2e}
----------------

The participation profile for each woman was generated at the beginning of the simulation in order to ensure the same participation profile for digital and screen-film screening. Participation was treated as a probabilistic parameter (see [appendix S1](#pone.0097459.s001){ref-type="supplementary-material"} for details) with values based on a probability of 78.7%for participation in initial screening and of 83.2% in successive screenings. When a woman was scheduled to participate in a screening round, a result was sampled using sensitivity values for women in the pre-clinical or clinical stage and specificity values for cancer-free women.

The proportion of false-negative results was obtained from a study on interval cancers [@pone.0097459-Domingo2]. False-negatives were defined as all interval cancers not classified as true interval cancers and included existing cancers not detected by mammography: false negatives, occult tumors, and minimal signs, which all together represent 57.5% of false negatives [@pone.0097459-Domingo2]. This percentage was applied to the overall number of interval cancers in the 20-year period and sensitivity was calculated. Sensitivity was assumed to be similar for both techniques [@pone.0097459-Bluekens1]--[@pone.0097459-Iared1] but was modeled as a probabilistic parameter and was sampled separately for each technique using the same statistical distribution with a mode of 86.66%. This allowed us to obtain scenarios with similar and different sensitivities favoring digital or screen-film mammography (see [appendix S1](#pone.0097459.s001){ref-type="supplementary-material"}).

Specificity was also treated as a probabilistic parameter and was calculated by stratifying by digital or screen-film mammography as well as by initial or successive screening, giving results of 88.8% for digital and 88.3% for screen-film mammography in the initial round and 95.8% for digital and 95.4% for screen-film screening mammography in successive rounds [@pone.0097459-Sala2]. These results coincided with the mode of the distributions for specificity (see [appendix S1](#pone.0097459.s001){ref-type="supplementary-material"}) and also allowed us to obtain scenarios with similar and different specificities favoring one or other technique.

In breast cancer screening, if a screening result is positive, a combination of additional (confirmatory) tests is assigned to the woman. Tests include additional mammographic projections, ultrasound, fine-needle aspiration cytology (FNAC), core biopsy, and open surgical biopsy. By using the Breast Cancer Screening Program database, the relative frequencies of the existing combinations of tests were calculated, stratifying by digital or screen-film mammography as well as by initial or successive screening.

Cancer detection {#s2f}
----------------

In our model cancer is detected inside and outside the screening program. The latter refers to nonparticipating women and interval cancers. The distribution of cancer stage at detection differs according to age and the screening round (initial or successive) as well as according to the detection setting. Clinical detection refers to cancers detected by clinical symptoms (interval cancers or cancers in nonparticipating women) and screening detection refers to those detected through a screening program (participating women). The stage distribution of screen-detected cancers differed according to digital or conventional mammography but that of clinical detected cancers was the same. In all cases, stage distribution was treated as a probabilistic parameter. See [appendix S1](#pone.0097459.s001){ref-type="supplementary-material"} for more details.

Unitary costs {#s2g}
-------------

The study was carried out from the perspective of a National Health System that includes in its portfolio both preventive programs and clinical treatments, as it is the case of Spain and the majority of European countries. That means that the same payer bears all the preventive and curative costs. The costs of both screen-film and digital mammography were obtained from the accounting system of a Spanish program [@pone.0097459-Sarriugarte1] before and after the process of switching from screen-film to digital mammography. The cost per woman screened was 39.29€ with screen-film and 42.28€ with digital mammography. These figures included all the program costs: human resources, equipment and structure, and corresponded to year 2009 [@pone.0097459-Sarriugarte1]. Amortization times for equipments (radiological and Picture Archiving and Communication System - PACS) were set at 10 years following accounting criteria.

The cost of diagnostic and screening mammograms was assumed to be the same, according to expert opinion. The reason is that, although a screening mammogram needs to be read by two radiologists and needs a higher number of projections, it takes an average of 3 minutes to read, while a diagnostic mammogram needs fewer projections and is read by one radiologist but reading takes longer.

The costs of breast ultrasound, FNAC, core needle biopsy and open surgical biopsy were obtained from the cost accounting systems of several Spanish hospitals[@pone.0097459-Cots1]. Women identified as having had these procedures in the Breast Cancer Screening Program were analyzed. The cost of a breast ultrasound was 16.69€. The cost of an FNAC included the cost of the procedure (80.22€), the cytological analysis of the sample (80.78€) and the consultation with the surgeon or gynecologist to inform the woman of the result (142.25€), amounting to 303.25€. The cost of a core needle biopsy included the procedure (113.54€), the histological analysis of the sample (14.37€) and the consultation with the surgeon or gynecologist to inform the woman of the result (142.25€), amounting to 270.16€. The cost of an open surgical biopsy was 1,388€ [@pone.0097459-Cots1].

The cost of treatment was obtained from a study [@pone.0097459-Corral1] that included incident breast cancer patients from 2000 to 2005. Patients were followed-up until December 2007 and the costs of treatment were included in addition to other variables such as cancer stage. Three different phases were considered for stages lower than stage IV: initial phase, follow-up and, if there was a recurrence, advanced phase. For stage IV, only the advanced phase was considered. For each phase, the mean duration and mean cost per month were calculated. For stages lower than IV, the probability of recurrence was also calculated. Within the model, each woman with a diagnosis of cancer was assigned a monthly cost, according to the detection stage and treatment phase. The costs and durations of the phases are shown in [Table 1](#pone-0097459-t001){ref-type="table"}. Original costs were based on the year 2005 and a cumulative Consumer Price Index (CPI) of 7.9% was applied to adjust them to the year 2009.

10.1371/journal.pone.0097459.t001

###### Costs of cancer treatment per month, cancer stage and treatment phase.
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            Initial phase   Follow-up   Advanced phase                              
  -- ----- --------------- ----------- ---------------- -------- ------- ---------- ----------
      CIS       5.75        2,006.25        115.25       132.10   2.75              
       I        9.40        2,006.25        111.60       291.87   7.85              
      II        10.62       2,236.92        110.38       577.35   14.68             
      III       11.11       2,236.92        109.89       737.65   35.38             
      IV                                                                  lifetime   3,438.71

CIS: Carcinoma in situ.

Similar monthly costs of the initial phase were found between DCIS and stage I, and between stages II and III.

The duration of the follow-up phase included the time from surgery until a maximum of 10 years, i.e. follow-up was calculated as 10 years (120 months) minus the duration of the initial phase except the first month.

The duration of follow-up for women assigned to have a recurrence was sampled from a Uniform distribution from the end of the initial phase to the end of the follow-up phase.

The costs of metastatic cancer were similar, regardless of whether the tumour was an initial stage IV cancer or a recurrence. Its duration was for the lifetime.

Probabilistic sensitivity analysis {#s2h}
----------------------------------

Crucial parameters such as sensitivity, specificity, the stage distribution of detected cancers and participation were included as probabilistic parameters (see [Appendix S1](#pone.0097459.s001){ref-type="supplementary-material"} for details on the distributions assigned). The results of the sensitivity analysis were stratified according to groups. The groups were created, based on the detection and recall rate: a group of simulation runs with better rates for digital mammography and another group with better rates for screen-film mammography were established. A better detection rate was defined as a rate at least 0.5‰ higher and a better recall rate was defined as a rate of at least 0.5% lower. Another group was defined by including those runs with a better detection rate and a higher proportion of noninvasive cancers detected through screening (at least 1% higher) with digital mammography.

Simulation analysis of results {#s2i}
------------------------------

Results were analyzed as the mean of 2,000 replications of the model with independent streams of random numbers. This sample size was calculated to detect a significant difference in overall costs at the 0.05 level using preliminary results with 100 replications, and allowed the results to be stratified for sensitivity analysis. The time units were years and the simulation horizon was 20 years, from 2010 to 2029.

The following results were used to validate the model: the number of invited women through time (by initial and successive screenings), the participation rate, the mean age of invited women, the number of mammograms over time (by initial and successive screenings), the recall rate, cancer detection rate, false-positive rate, false-negative and interval cancer rate, the distribution of additional tests, the distribution of cancer stage (pre-clinical and clinical), and life expectancy. Validation results were shown to the research team using graphics through time and compared to published and unpublished data on Spanish programs. The distributions of the probabilistic parameters were also shown and its relationship with outcomes explained, as well as published data from other countries was presented to contextualize the need to include them as probabilistic parameters. The research team checked the validation results and the model was considered as valid, credible and useful for the purposes of the study.

Budget Impact Analysis {#s2j}
----------------------

Budget impact analysis requires the inclusion of the entire population involved in a system each year [@pone.0097459-Mauskopf2]. Thus, individual women entering and exiting the model were simulated throughout the simulation horizon. Each year, the impact on the budget was calculated according to the difference between the two alternatives (screen-film minus digital) in overall costs, screening costs, and the costs of additional tests and cancer treatment. The cost results for each technique and the confidence intervals for the cost differences were shown for years 2010, 2015, 2020, 2025 and 2029. Costs were not discounted, according to the published good practices for budget impact analysis [@pone.0097459-Mauskopf2].

Results {#s3}
=======

The model started with a target population of 100,000 women aged 50--69 years. Over the 20 simulated years, 151,960 women were dynamically incorporated into the target population, making a total of 251,960 women invited to the program and resulting in more than 731,400 screening mammograms, of which 15.3% corresponding to initial screening ([Table 2](#pone-0097459-t002){ref-type="table"}).

10.1371/journal.pone.0097459.t002

###### Twenty-year cumulative results on health and validation outcomes, according to type of mammogram.

![](pone.0097459.t002){#pone-0097459-t002-2}

                                               Digital mammography   Screen-film mammography                     
  ------------------------------------------- --------------------- ------------------------- --------- -------- --
  **Overall data**                                                                                               
  Invited women                                      251,960                                   251,960           
   Initial population                                100,000                                   100,000           
   New women entering target population              151,960                                   151,960           
  Screening mammograms                               731,510                                   731,506           
   Initial screening                                 111,718                  15.3%            111,718   15.3%   
   Successive screening                              619,792                  84.7%            619,788   84.7%   
  **Recall for further assessment**                                                                              
  Recall rate                                        44,536                   6.1%             47,931     6.6%   
  Further assessments                                                                                            
   Additional mammograms                             19,085                   2.6%             28,529     3.9%   
   Ultrasound                                        34,241                   4.7%             37,809     5.2%   
   Fine-needle aspiration cytology                   11,812                   1.6%             20,729     2.8%   
   Core biopsy                                        2,725                   0.4%              4,611     0.6%   
   Open surgical biopsy                                302                    0.04%             1,544     0.2%   
  False positive rate                                39,833                   5.4%             43,226     5.9%   
   Initial screening                                 12,812                   11.5%            13,275    11.9%   
   Successive screening                              27,021                   4.4%             29,951     4.8%   
  **Cancer detection**                                                                                           
  Cancer detection rate                               4,702                  0.643%             4,704    0.643%  
   Carcinoma *in situ*                                1,008                   21.4%              841     17.9%   
   Invasive cancers                                   3,694                   78.6%             3,864    82.1%   
    Stage I                                           1,944                   41.3%             2,073    44.1%   
    Stage II                                          1,380                   29.4%             1,230    26.1%   
    Stage III                                          350                    7.4%               549     11.7%   
    Stage IV                                           20                     0.4%               13       0.3%   
  Interval cancer rate                                1,588                  0.217%             1,587    0.217%  
   True interval cancers (% of all cancers)           1,271                   27.0%             1,271    27.0%   
   False negatives (% of all cancers)                  316                    6.7%               316      6.7%   
  **Mortality**                                                                                                  
  Deaths due to cancer                                1,887                  0.749%             1,942    0.771%  
   Carcinoma *in situ*                                 16                     0.9%               14       0.7%   
   Stage I                                             444                    23.6%              463     23.9%   
   Stage II                                            790                    41.9%              791     40.7%   
   Stage III                                           424                    22.5%              519     26.7%   
   Stage IV                                            159                    8.5%               155      8.0%   

The recall rate was 6.1% for digital and 6.6% for screen-film mammography. Fewer additional tests were required with digital mammography ([Table 2](#pone-0097459-t002){ref-type="table"}). The false positive rate was 5.4% for digital mammography and 5.9% for screen-film mammography. The cancer detection rate (0.64%), the interval cancer rate (0.22%) and the mortality rate (about 0.76%) were similar between digital and screen-film mammography ([Table 2](#pone-0097459-t002){ref-type="table"}).

[Table 3](#pone-0097459-t003){ref-type="table"} and [Figure 2](#pone-0097459-g002){ref-type="fig"} show the budget impact of digital mammography in the short and the long term. The cost of the screening program with digital mammography was always higher but was offset by the savings due to a lower need for additional tests. Reductions in treatment costs were an additional saving. [Figure 2](#pone-0097459-g002){ref-type="fig"} shows the yearly difference between the two screening modalities. Confidence intervals in [Table 3](#pone-0097459-t003){ref-type="table"} show significant savings in overall costs and the costs of additional tests and treatment in the short and long term. Moreover, the savings in treatment costs were clear and increased over time. The overall cost savings were 165,540€ (95%CI from 133,253 to 197,827) after 1 year, 1,115,857€ (95%CI from 932,147 to 1,299,567) at 10 years and 2,866,124€ (95%CI from 2,492,610 to 3,239,638) at 20 years. This saving represented reductions/reduced costs/savings of 3.0%, 4.5% and 8.1%, respectively, over the overall cost of screening with screen-film mammography.

![Budget impact analysis.\
Differences in cost between screen-film and digital mammography, by type of cost and year. Positive differences indicate cost savings with digital mammography.](pone.0097459.g002){#pone-0097459-g002}

10.1371/journal.pone.0097459.t003

###### Budget impact analysis of digital mammography compared with screen-film mammography.
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                                                                        Year                                                               
  ------------------------------------ ---------------------- ------------------------ ------------------------ -------------------------- --------------------------
  Digital mammography                                                                                                                      
  Overall cost                               5,429,104               15,546,355               23,922,992                29,002,023                 32,420,266
   Screening                                 1,318,641               1,437,720                1,591,541                 1,671,728                  1,722,550
   Additional tests                           254,246                 290,016                  316,109                   328,451                    334,096
   Cancer treatment                          3,856,217               13,818,618               22,015,343                27,001,844                 30,363,620
                                                                                                                                           
  Screen-film mammography                                                                                                                  
  Overall cost                               5,594,644               15,996,017               25,038,849                31,190,348                 35,286,390
   Screening                                 1,225,388               1,336,029                1,478,975                 1,553,505                  1,600,717
   Additional tests                           475,898                 542,930                  588,531                   609,703                    629,704
   Cancer treatment                          3,893,358               14,117,058               22,971,343                29,027,141                 33,055,968
  Difference (Screen-film - Digital)                                                                                                       
  Overall cost                                165,540                 449,662                 1,115,857                 2,188,325                  2,866,124
  95%CI                                 \[133,253; 197,827\]    \[344,495; 554,830\]    \[932,147; 1,299,567\]   \[1,897,187; 2,479,463\]   \[2,492,610; 3,239,638\]
   Screening                                  −93,253                 −101,692                 −112,566                  −118,224                   −121,833
   95%CI                                \[−93,517; −92,988\]   \[−101,966; −101,417\]   \[−112,873; −112,259\]    \[−118,544; −117,903\]     \[−122,167; −121,498\]
   Additional tests                           221,652                 252,914                  272,423                   281,252                    295,608
   95%CI                                \[217,116; 226,187\]    \[248,017; 257,812\]     \[267,096; 277,750\]      \[275,884; 286,620\]       \[289,974; 301,242\]
   Cancer treatment                            37,141                 298,440                  956,000                  2,025,297                  2,692,348
   95%CI                                 \[5,298; 68,984\]      \[193,516; 403,364\]    \[772,553; 1,139,447\]   \[1,734,283; 2,316,311\]   \[2,319,115; 3,065,582\]

CI: Confidence Interval.

[Figure 3](#pone-0097459-g003){ref-type="fig"} shows the results of the sensitivity analysis for the groups of runs with better detection and recall rates for digital (n = 921) and for screen-film (n = 469) mammography. Both groups showed a significant net benefit of digital mammography.

![Sensitivity analysis results.\
DM better (n = 921 runs): Digital mammography higher detection rate and lower recall rate, or digital higher detection rate and similar recall rate, or digital lower recall rate and similar detection rate. SFM better (n = 469 runs): Screen-film mammography higher detection rate and lower recall rate, or SFM higher detection rate and similar recall rate, or SFM lower recall rate and similar detection rate. Intermediate scenario (n = 610 runs, not shown): Digital higher detection rate and SFM lower recall rate, or digital lower recall rate and SFM higher detection rate, or both similar detection and recall rates. CI: Confidence Interval.](pone.0097459.g003){#pone-0097459-g003}

The results of runs with a better detection rate and a higher proportion of noninvasive cancers with digital mammography showed higher costs of digital mammography in the short term, but significant savings in the long term (after the 10^th^ year, data not shown).

Discussion {#s4}
==========

The main finding of the budget impact analysis was that a switch to digital mammography results in net savings if, in addition to screening costs, the costs of additional tests and treatment are taken into account, with similar screening results. The model was run for an initial population of 100,000 women aged 50--69 years, which, according to the current structure of the Spanish population, would correspond to an overall population of about 860,000 inhabitants.

Several studies [@pone.0097459-Ciatto1]--[@pone.0097459-MartnezCantarero1] have reported that digital mammography is more expensive than screen-film mammography. However, the actual economic impact should take into account all the costs derived from a population-based screening program, that is, the costs of confirmatory tests and those of treating detected cancers.

To our knowledge, this is the first study to perform a budget impact analysis of digital mammography for breast cancer screening. Previous studies have consisted of cost comparisons [@pone.0097459-Ciatto1], [@pone.0097459-MartnezCantarero1] and cost-effectiveness studies [@pone.0097459-Wang1], [@pone.0097459-Tosteson1] and have included the costs of screening only. Our results show that the savings due to fewer additional tests alone offset the higher cost of screening with digital mammography. In addition, the greatest savings corresponded to treatment costs.

Our model shows that, although the differences in recall rate between digital and screen-film mammography are small in magnitude, they result in substantial cost savings in the long term as the lower recall rate with digital mammography results in fewer adverse events and additional tests with a consequent reduction in the negative impact on women. The most frequent additional test with digital mammography was one ultrasound scan (about 30%), while for conventional mammography a combination of ultrasound and FNAC was used (about 22%). Because the differences in recall and detection rate between screen-film and digital mammography are controversial, sensitivity and specificity were included as probabilistic parameters, meaning that some simulations were run with better sensitivities and/or specificities for digital mammography, others were run with better sensitivities and/or specificities for screen-film mammography, other simulations were run combining opposite directions for each parameter and still others were run with similar parameters. The results of the sensitivity analysis performed with the results of detection and recall rates demonstrated that, for all subgroups, the switch to digital mammography produced significant net savings in the long term, indicating that our results are consistent and robust concerning differences in the detection and recall rates between digital and screen-film mammography. The sensitivity analysis stratified by excess detection of carcinoma *in situ* with digital mammography also showed net savings in the long term (data not shown), despite excess costs in the short term.

The model\'s parameters were mostly obtained from Spanish breast cancer screening programs that followed the standards of the European guidelines, thus conferring homogeneity to the model. However, the parameters related to the natural history of the disease, such as the sojourn time in the pre-clinical stage, although adapted to our population, were based on US data.

Treatment costs may have been underestimated because medication criteria corresponded to 2000--2005 and costs to 2005 and more expensive chemotherapy treatments have been introduced since then. In addition, treatment costs included those of women with cancers detected within the simulation horizon only. Although this consideration did not pose a limitation to our objective of comparing digital with screen-film mammography screening, it did lead to underestimation of treatment and overall costs, especially in the short term.

Given that our objective was to compare the population-based screening program using one technology versus the same program using the other, the costs and inefficiencies associated to the process itself of switching from screen-film to digital mammography have not been included [@pone.0097459-vandeWetering1]. Further research would be needed to estimate the economic impact of the process of change and how increased short-term costs may hamper implementation of digital mammography throughout all the Spanish screening units.

In conclusion, switching from screen-film to digital mammography within a population-based breast cancer screening program reduces expense in the long term in addition to providing technical advantages. The higher expense of digital screening is offset by the reduction in additional tests. These results were consistent across distinct scenarios representing the different results obtained in European breast cancer screening programs.
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